Roche Gets CE Mark for Latest Covid-19 Nasal Antigen Test

   By Joshua Kirby

Roche Holding AG said Monday that it has received a CE mark for its latest rapid Covid-19 test, which will now be available in applicable European countries from the middle of this month.

The Swiss pharmaceuticals company said it had been granted the European regulatory approval for its Rapid Antigen Test Nasal. The new test collects samples from the frontal part of the nose, rather than deeper inside, making it less uncomfortable. This means it can also be carried out by patients themselves, reducing physical contact between patients and health-care workers, Roche said.

The test follows a rapid antigen test launched by the company in September. Both tests were launched in partnership with SD Biosensor Inc., which is now applying for emergency approval for the latest test from the U.S. Food & Drug Administration, Roche added.

Write to Joshua Kirby at joshua.kirby@dowjones.com; @joshualeokirby

(END) Dow Jones Newswires

February 01, 2021 12:04 ET (17:04 GMT)

Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024